7 recruiting, 1 unknown. 5 Phase 1, 5 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 4, Unknown 1 |
| Phase 2 | 5 | Recruiting 5 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Multitude Therapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Recruiting | Multitude Therapeutics Inc. | 512 | 2026-09-30 | 2026-10-26 |
| AMT-116 in Combination With AK112 in Patients With Lung Cancer AMT-116, AK112 - Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Multitude Therapeutics Inc. | 118 | 2026-06-29 | 2026-08-10 |
| A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer AMT-676, 5-FU, Leucovorin - Colorectal Cancer | Phase 2 | Recruiting | Multitude Therapeutics Inc. | 180 | 2026-04-29 | 2026-08-27 |
| AMT-676 in Patients With Advanced Solid Tumors AMT-676 - Advanced Solid Tumors | Early Phase 1 | Recruiting | Multitude Therapeutics Inc. | 24 | 2024-06-18 | 2026-05-18 |
| AMT-116 in Patients with Solid Tumors AMT-116 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Multitude Therapeutics Inc. | 144 | 2024-05-07 | 2025-01-17 |
| AMT-253 in Patients With Advanced Solid Tumours AMT-253 for injection - Malignant Melanoma, Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Multitude Therapeutics Inc. | 96 | 2024-01-31 | 2025-09-05 |
| AMT-116 in Patients With Advanced Solid Tumors AMT-116 - Advanced Solid Tumor | Phase 1 | Recruiting | Multitude Therapeutics Inc. | 80 | 2023-07-25 | 2025-08-17 |
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
Adenocarcinoma of Lung (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Bevacizumab (1) · Cetuximab (1) · Docetaxel (1) · Fluorouracil (1) · Injections (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · Ramucirumab (1)
China (6) · Australia (4) · American Samoa (2) · United States (2)
Jermaine Coward (2) · Catherine Shannon (1) · Mihitha Ariyapperuma (1) · Richardson Gary (1) · Sarwan Bishnoi (1) · Steven Kao (1)